Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Operating Expenses (2020 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Other Operating Expenses for 6 consecutive years, with -$4.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses fell 458.41% year-over-year to -$4.8 million, compared with a TTM value of -$2.4 million through Sep 2025, down 190.29%, and an annual FY2024 reading of $3.0 million, down 22.24% over the prior year.
  • Other Operating Expenses was -$4.8 million for Q3 2025 at Kiora Pharmaceuticals, down from -$640633.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $4.8 million in Q3 2023 and bottomed at -$4.8 million in Q3 2025.
  • Average Other Operating Expenses over 5 years is $523774.9, with a median of $179000.0 recorded in 2022.
  • The sharpest move saw Other Operating Expenses surged 3235.77% in 2024, then tumbled 467.7% in 2025.
  • Year by year, Other Operating Expenses stood at $4.0 million in 2021, then crashed by 76.19% to $950000.0 in 2022, then plummeted by 86.69% to $126454.0 in 2023, then soared by 3235.77% to $4.2 million in 2024, then tumbled by 214.96% to -$4.8 million in 2025.
  • Business Quant data shows Other Operating Expenses for KPRX at -$4.8 million in Q3 2025, -$640633.0 in Q2 2025, and -$1.1 million in Q1 2025.